Enanta Pharmaceuticals

Enanta Pharmaceuticals company information, Employees & Contact Information

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic and acute hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

Company Details

Employees
152
Founded
-
Address
500 Arsenal Street, Watertown,ma 02472,united States
Phone
6176070530
Email
in****@****nta.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
enanta.com
HQ
Watertown, MA
Looking for a particular Enanta Pharmaceuticals employee's phone or email?

Enanta Pharmaceuticals Questions

News

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 - Yahoo Finance

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 Yahoo Finance

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Business Wire

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Business Wire

Clinical-Stage Biotech Enanta Pharmaceuticals Sets Triple Conference Schedule for September 2025 - Stock Titan

Clinical-Stage Biotech Enanta Pharmaceuticals Sets Triple Conference Schedule for September 2025 Stock Titan

Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire

Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. - Yahoo Finance

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. Yahoo Finance

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 - Yahoo Finance

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 Yahoo Finance

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series - Business Wire

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series Business Wire

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults - Business Wire

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults Business Wire

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) - Yahoo Finance

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) Yahoo Finance

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 - Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 Business Wire

Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults - Business Wire

Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults Business Wire

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union - Business Wire

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union Business Wire

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET - Business Wire

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET Business Wire

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit - Business Wire

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 - Yahoo Finance

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 Yahoo Finance

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer - Business Wire

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer Business Wire

Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET - Business Wire

Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET Business Wire

Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline - The AI Journal

Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline The AI Journal

Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors - Business Wire

Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors Business Wire

Enanta Pharmaceuticals Announces the Appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology - Business Wire

Enanta Pharmaceuticals Announces the Appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology Business Wire

Enanta Pharmaceuticals Chief Medical Officer Nathalie Adda to Retire - citybiz

Enanta Pharmaceuticals Chief Medical Officer Nathalie Adda to Retire citybiz

Enanta Pharmaceuticals Announces Pricing of Initial Public Offering - Yahoo Movies UK

Enanta Pharmaceuticals Announces Pricing of Initial Public Offering Yahoo Movies UK

Top Enanta Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant